125.98
price up icon2.27%   2.925
 
loading
Repligen Corp stock is traded at $125.98, with a volume of 382.40K. It is up +2.27% in the last 24 hours and down -13.87% over the past month. Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$123.06
Open:
$123.86
24h Volume:
382.40K
Relative Volume:
0.55
Market Cap:
$7.09B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-406.40
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-4.76%
1M Performance:
-13.87%
6M Performance:
+4.37%
1Y Performance:
-18.71%
1-Day Range:
Value
$123.37
$127.03
1-Week Range:
Value
$118.72
$135.18
52-Week Range:
Value
$102.97
$175.77

Repligen Corp Stock (RGEN) Company Profile

Name
Name
Repligen Corp
Name
Phone
(781) 449-9560
Name
Address
41 SEYON STREET, WALTHAM, MA
Name
Employee
1,778
Name
Twitter
@repligen
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
RGEN's Discussions on Twitter

Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Instruments & Supplies icon
RGEN
Repligen Corp
125.81 6.93B 633.51M -8.10M 131.26M -0.31
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
500.96 176.65B 10.06B 2.88B 2.49B 7.876
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
171.23 49.56B 21.92B 1.76B 2.63B 6.1223
Medical Instruments & Supplies icon
ALC
Alcon Inc
83.90 40.50B 10.19B 1.05B 1.38B 2.1044
Medical Instruments & Supplies icon
RMD
Resmed Inc
258.36 37.63B 5.40B 1.49B 1.78B 10.12
Medical Instruments & Supplies icon
MDLN
Medline Inc
43.28 36.02B 28.43B 1.16B 1.26B 1.4457

Repligen Corp Stock (RGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-01-25 Initiated HSBC Securities Buy
Sep-22-25 Upgrade Evercore ISI In-line → Outperform
Jul-22-25 Resumed Stephens Overweight
Jun-24-25 Initiated Barclays Overweight
Apr-29-25 Upgrade Wolfe Research Peer Perform → Outperform
Mar-18-25 Initiated Evercore ISI In-line
Feb-10-25 Initiated TD Cowen Buy
Dec-17-24 Initiated Canaccord Genuity Hold
Nov-14-24 Initiated Wolfe Research Peer Perform
Aug-28-24 Initiated Wells Fargo Overweight
Jun-26-24 Upgrade Deutsche Bank Hold → Buy
Jun-18-24 Initiated Guggenheim Neutral
Dec-04-23 Downgrade The Benchmark Company Buy → Hold
Jul-20-23 Initiated Wells Fargo Overweight
Jul-05-23 Resumed JP Morgan Overweight
Mar-28-23 Initiated The Benchmark Company Buy
Dec-14-22 Initiated Deutsche Bank Hold
Dec-07-22 Initiated RBC Capital Mkts Sector Perform
Jul-20-22 Initiated UBS Buy
Oct-14-21 Initiated Exane BNP Paribas Outperform
Nov-10-20 Initiated KeyBanc Capital Markets Overweight
Aug-24-20 Reiterated H.C. Wainwright Buy
Jun-30-20 Reiterated H.C. Wainwright Buy
May-07-20 Reiterated H.C. Wainwright Buy
Mar-23-20 Reiterated H.C. Wainwright Buy
Nov-15-19 Initiated Stifel Buy
Nov-01-19 Upgrade First Analysis Sec Outperform → Strong Buy
Oct-15-19 Initiated SVB Leerink Outperform
Aug-28-19 Reiterated First Analysis Sec Outperform
Aug-23-19 Resumed Stephens Overweight
Jul-22-19 Upgrade H.C. Wainwright Neutral → Buy
Dec-17-18 Upgrade CL King Neutral → Buy
Nov-12-18 Downgrade CL King Buy → Neutral
Sep-26-18 Initiated H.C. Wainwright Neutral
Dec-08-17 Initiated Citigroup Buy
Dec-05-17 Initiated JP Morgan Overweight
Nov-13-17 Initiated CL King Buy
Oct-02-17 Upgrade First Analysis Sec Equal-Weight → Overweight
Jul-21-17 Initiated William Blair Outperform
Feb-13-17 Upgrade Piper Jaffray Neutral → Overweight
View All

Repligen Corp Stock (RGEN) Latest News

pulisher
08:28 AM

Repligen Corporation $RGEN Shares Sold by TD Asset Management Inc - MarketBeat

08:28 AM
pulisher
07:19 AM

NZS Capital LLC Has $26.30 Million Stake in Repligen Corporation $RGEN - MarketBeat

07:19 AM
pulisher
Mar 03, 2026

Repligen (RGEN) COO uses 3,911 shares to cover tax withholding - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Repligen (RGEN) CEO reports tax-withholding share dispositions in Form 4 - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Repligen (RGEN) director uses 9,897 shares to cover RSU taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Repligen (RGEN) CFO stock withheld to cover RSU tax obligations - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Repligen (RGEN) SVP uses company shares to cover RSU taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Repligen (RGEN) CPO has shares withheld to cover RSU tax bill - Stock Titan

Mar 03, 2026
pulisher
Mar 02, 2026

Repligen Corporation (RGEN) Investor Outlook: Exploring a 44.7% Potential Upside in the Bioprocessing Sector - DirectorsTalk Interviews

Mar 02, 2026
pulisher
Mar 02, 2026

Repligen Corporation $RGEN Position Boosted by Royce & Associates LP - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

3 Reasons to Avoid RGEN and 1 Stock to Buy Instead - Finviz

Mar 02, 2026
pulisher
Mar 01, 2026

Artisan Partners Limited Partnership Has $28.44 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat

Mar 01, 2026
pulisher
Feb 28, 2026

Primecap Management Co. CA Has $24.98 Million Stock Position in Repligen Corporation $RGEN - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

Repligen (NASDAQ:RGEN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know - Yahoo Finance

Feb 27, 2026
pulisher
Feb 27, 2026

Repligen Corp (RGEN) Shares Down 3.09% on Feb 27 - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Oversold Conditions For Repligen (RGEN) - Nasdaq

Feb 27, 2026
pulisher
Feb 27, 2026

Decoding Repligen Corp (RGEN): A Strategic SWOT Insight - GuruFocus

Feb 27, 2026
pulisher
Feb 26, 2026

Repligen (NASDAQ: RGEN) maps 2025 bioprocessing market, debt and control risks - Stock Titan

Feb 26, 2026
pulisher
Feb 25, 2026

A Glimpse Into The Expert Outlook On Repligen Through 6 Analysts - Benzinga

Feb 25, 2026
pulisher
Feb 25, 2026

Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar

Feb 25, 2026
pulisher
Feb 25, 2026

Barclays Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Barclays Adjusts Repligen (RGEN) Target Price Amid Overweight Ra - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Wells Fargo Lowers Price Target for RGEN, Maintains Overweight R - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz

Feb 25, 2026
pulisher
Feb 25, 2026

Repligen (NASDAQ:RGEN) Price Target Lowered to $180.00 at Wells Fargo & Company - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Evercore ISI Group Lowers Price Target for Repligen (RGEN) to $1 - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

KeyBanc reiterates Repligen stock rating on product momentum - Investing.com

Feb 25, 2026
pulisher
Feb 25, 2026

How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products - Yahoo Finance

Feb 25, 2026
pulisher
Feb 24, 2026

Repligen (RGEN) Return To Profitability Tests Bullish Growth Narrative In Q4 2025 Results - simplywall.st

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Corporation Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Or - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen earnings beat by $0.05, revenue topped estimates By Investing.com - Investing.com South Africa

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Q4 Earnings Call Highlights - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Q4 2025 Earnings Beat Estimates, Provides 2026 OutlookNews and Statistics - IndexBox

Feb 24, 2026
pulisher
Feb 24, 2026

Earnings call transcript: Repligen Q4 2025 earnings surpass expectations - Investing.com

Feb 24, 2026
pulisher
Feb 24, 2026

Earnings call transcript: Repligen Q4 2025 earnings surpass expectations By Investing.com - Investing.com Canada

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen (RGEN) Beats Q4 Revenue Expectations with Strong Organi - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Corp (NASDAQ:RGEN) Stock Falls Despite Q4 Earnings Beat as 2026 Guidance Disappoints - ChartMill

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen earnings beat by $0.05, revenue topped estimates - Investing.com

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations - Finviz

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen: Fourth Quarter Earnings Overview - Bitget

Feb 24, 2026
pulisher
Feb 24, 2026

REPLIGEN ($RGEN) Releases Q4 2025 Earnings - Quiver Quantitative

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen beats Q4 estimates but guides below consensus for 2026 - Investing.com

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen: Q4 Earnings Snapshot - marketscreener.com

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Q4 Earnings Report: What Investors Need to Know - Benzinga

Feb 24, 2026
pulisher
Feb 24, 2026

Repligen Corporation Reports Q4 and Full Year 2025 Financial Results - TradingView

Feb 24, 2026
pulisher
Feb 24, 2026

Earnings Flash (RGEN) Repligen Corporation Reports Q4 Revenue $197.9M, vs. FactSet Est of $192.9M - marketscreener.com

Feb 24, 2026

Repligen Corp Stock (RGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Repligen Corp Stock (RGEN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
MUIR GLENN P
Director
Dec 16 '25
Option Exercise
26.12
3,366
87,920
36,622
$71.49
price up icon 0.98%
$182.71
price up icon 0.04%
medical_instruments_supplies COO
$81.36
price down icon 2.45%
$75.41
price down icon 0.07%
medical_instruments_supplies WST
$252.01
price up icon 0.12%
$43.15
price down icon 2.76%
Cap:     |  Volume (24h):